» Articles » PMID: 36193082

Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment Through Network Pharmacology and Bioinformatics Analysis

Overview
Publisher Wiley
Date 2022 Oct 4
PMID 36193082
Authors
Affiliations
Soon will be listed here.
Abstract

Matrine and glycyrrhizin are representative active ingredients of traditional Chinese medicine (TCM) used in clinical practice. Studies have demonstrated that matrine has antitumor pharmacological effects and that glycyrrhizin protects liver function. However, the potential bioactive compounds and mechanisms remain unknown, as well as whether they have synergistic effects in killing cancer cells and protecting liver cells. To investigate the synergistic effects and mechanism of matrine combined with glycyrrhizin in hepatocellular carcinoma (HCC) treatment, we used both network pharmacology and bioinformatics analyses. First, the chemical gene interaction information of matrine and glycyrrhizin was obtained from the PubChem database. The pathogenic genes of HCC were accessed from five public databases. The RNA sequencing data and clinical information of HCC patients were downloaded from The Cancer Genome Atlas (TCGA). Next, the overlapping genes among the potential targets of matrine and glycyrrhizin and HCC-related targets were determined using bioinformatics analysis. We constructed the drug-target interaction network. Prognosis-associated genes were acquired through the univariate Cox regression model and Lasso-Cox regression model. The results were verified by the International Cancer Genome Consortium (ICGC) database. Finally, we predicted the immune function of the samples. The drug-target interaction network consisted of 10 matrine and glycyrrhizin targets. We selected a Lasso-Cox regression model consisting of 3 differentially expressed genes (DEGs) to predict the efficacy of the combination in HCC. Subsequently, we successfully predicted the overall survival of HCC patients using the constructed prognostic model and investigated the correlation of the immune response. Matrine and glycyrrhizin have synergistic effects on HCC. The model we obtained consisted of three drug-target genes by Lasso-Cox regression analysis. The model independently predicted the combined effect of matrine and glycyrrhizin in HCC treatment and OS, which will be helpful for guiding clinical treatment. The prognostic model was correlated with the immune cells and immune checkpoints of patients, which had an adjuvant effect on HCC immunotherapy. Matrine and glycyrrhizin can have therapeutic effects on HCC by promoting the production or enhancing the core gene activity in the drug network and improving the immune system function of patients.

Citing Articles

Application of network pharmacology in synergistic action of Chinese herbal compounds.

Duan X, Wang N, Peng D Theory Biosci. 2024; 143(3):195-203.

PMID: 38888845 DOI: 10.1007/s12064-024-00419-2.


Comparative Efficacy of East Asian Herbal Formulae Containing Astragali Radix-Cinnamomi Ramulus Herb-Pair against Diabetic Peripheral Neuropathy and Mechanism Prediction: A Bayesian Network Meta-Analysis Integrated with Network Pharmacology.

Jo H, Baek E, Lee D Pharmaceutics. 2023; 15(5).

PMID: 37242603 PMC: 10221388. DOI: 10.3390/pharmaceutics15051361.


Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma.

Ding R, Zhao C, Jing Y, Chen R, Meng Q BMC Med Genomics. 2023; 16(1):81.

PMID: 37081465 PMC: 10116671. DOI: 10.1186/s12920-023-01504-z.


The role of the stemness index-associated signature in the analysis of the tumorigenesis of liver cancer patients of different races.

Liu D, Wen G, Song C, Xu Z, Ren F, Zhao Z Am J Cancer Res. 2023; 13(3):802-817.

PMID: 37034207 PMC: 10077047.


Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma.

Chuanbing Z, Zhengle Z, Ruili D, Kongfan Z, Jing T Biomolecules. 2023; 13(1).

PMID: 36671437 PMC: 9856074. DOI: 10.3390/biom13010052.

References
1.
Gerbal-Chaloin S, Dume A, Briolotti P, Klieber S, Raulet E, Duret C . The WNT/β-catenin pathway is a transcriptional regulator of CYP2E1, CYP1A2, and aryl hydrocarbon receptor gene expression in primary human hepatocytes. Mol Pharmacol. 2014; 86(6):624-34. DOI: 10.1124/mol.114.094797. View

2.
Wermuth C . Multitargeted drugs: the end of the "one-target-one-disease" philosophy?. Drug Discov Today. 2004; 9(19):826-7. DOI: 10.1016/S1359-6446(04)03213-1. View

3.
Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X . Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2009; 38(Database issue):D787-91. PMC: 2808971. DOI: 10.1093/nar/gkp1014. View

4.
Gao J, He T, Li Y, Wang Y . A traditional Chinese medicine formulation consisting of Rhizoma Corydalis and Rhizoma Curcumae exerts synergistic anti-tumor activity. Oncol Rep. 2009; 22(5):1077-83. DOI: 10.3892/or_00000539. View

5.
Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View